At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,338 enrolled
Drug / intervention
Selaradrug
Likely dose
Selara 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Eplerenone Observational Study Of Safety And Efficacy Evaluation To Normalize Blood Pressure For Clinical Effectiveness
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·observational·Posted Sep 9, 2008·Updated Dec 22, 2020
In Brief
An observational study evaluating Selara for Hypertension. Completed, enrolled 3,338 participants.
Detailed Summary
To collect the efficacy and safety information of Eplerenone on patients with hypertension related to their appropriate use in daily practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedSep 2008
Primary CompletionDec 2012
TodayJul 2026
First PostedSep 9, 2008
Enrollment StartJun 1, 2008
Primary CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 17.8 years ago
Interventions
Selaradrug
Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Selara may be administered with or without food.